Nektar Therapeutics (NKTR) Stock Forecast & Price Target

Compare

1,421 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NKTR Analyst Ratings

Moderate Buy

4 Buy

1 Hold

1 Sell

Based on 6 analysts giving stock ratings to

Nektar

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NKTR Stock 12 Month Forecast

Average Price Target

$98.50

▲(231.87%Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $98.50 with a high forecast of $120.00 and a low forecast of $69.00. The average price target represents a 231.87% change from the last price of $29.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","64":"$64","121":"$121","35.5":"$35.5","92.5":"$92.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":98.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$98.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$69.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,35.5,64,92.5,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.95,20.26153846153846,28.573076923076922,36.88461538461539,45.19615384615385,53.50769230769231,61.81923076923077,70.13076923076923,78.4423076923077,86.75384615384615,95.06538461538462,103.37692307692308,111.68846153846154,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.95,18.607692307692307,25.265384615384612,31.92307692307692,38.58076923076923,45.238461538461536,51.89615384615384,58.55384615384615,65.21153846153845,71.86923076923077,78.52692307692307,85.18461538461538,91.84230769230768,{"y":98.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.95,16.338461538461537,20.726923076923075,25.115384615384613,29.50384615384615,33.89230769230769,38.280769230769224,42.669230769230765,47.05769230769231,51.44615384615385,55.834615384615375,60.22307692307692,64.61153846153846,{"y":69,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.1,"date":1701388800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":24.75,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.05,"date":1717200000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$98.50

Lowest Price Target$69.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$30

Hold

1.08%

Upside

Reiterated

06/26/25

The overall stock score reflects the significant financial challenges faced by Nektar Therapeutics, despite strong technical analysis and positive corporate events. The company's ongoing losses and valuation difficulties weigh heavily, although recent trial successes and strong technical momentum provide a positive outlook. The earnings call provides a mixed signal with financial strength but litigation concerns.

Arthur He CFAH.C. Wainwright

H.C. Wainwright

$6.5→$120

Buy

304.31%

Upside

Reiterated

06/25/25

Nektar price target raised to $120 from $6.50 at H.C. WainwrightNektar price target raised to $120 from $6.50 at H.C. Wainwright

Yasmeen RahimiPiper Sandler

Piper Sandler

$105

Buy

253.77%

Upside

Reiterated

06/25/25

Piper Sandler Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)

Jessica FyeJ.P. Morgan

J.P. Morgan

―

Sell

―

Reiterated

06/24/25

J.P. Morgan Sticks to Its Sell Rating for Nektar Therapeutics (NKTR)

Andy HsiehWilliam Blair

William Blair

―

Hold

―

Reiterated

06/24/25

William Blair Sticks to Their Hold Rating for Nektar Therapeutics (NKTR)

Julian HarrisonBTIG

BTIG

$60→$100

Buy

236.93%

Upside

Reiterated

06/24/25

Nektar price target raised to $100 from $60 at BTIGNektar price target raised to $100 from $60 at BTIG

Roger SongJefferies

Jefferies

$69

Buy

132.48%

Upside

Reiterated

06/24/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jay OlsonOppenheimer

Oppenheimer

$90

Buy

203.23%

Upside

Upgraded

03/14/25

Nektar upgraded at Oppenheimer on upcoming mid-stage trial readoutOppenheimer upgraded the biopharma to Outperform from Perform, citing a favorable valuation setup ahead of a mid-stage trial readout for its eczema therapy rezpegaldesleukin.

Mayank MamtaniB.Riley Financial

B.Riley Financial

$60

Buy

102.16%

Upside

Reiterated

02/28/25

Analysts Conflicted on These Healthcare Names: Lemaitre Vascular (NASDAQ: LMAT), Catalyst Pharma (NASDAQ: CPRX) and Nektar Therapeutics (NASDAQ: NKTR)

Anthony ButlerRodman & Renshaw

Rodman & Renshaw

$30

Buy

1.08%

Upside

Initiated

06/28/24

Nektar initiated with a Buy at Rodman & RenshawNektar initiated with a Buy at Rodman & Renshaw

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$30

Hold

1.08%

Upside

Reiterated

06/26/25

Arthur He CFAH.C. Wainwright

H.C. Wainwright

$6.5→$120

Buy

304.31%

Upside

Reiterated

06/25/25

Nektar price target raised to $120 from $6.50 at H.C. WainwrightNektar price target raised to $120 from $6.50 at H.C. Wainwright

Yasmeen RahimiPiper Sandler

Piper Sandler

$105

Buy

253.77%

Upside

Reiterated

06/25/25

Piper Sandler Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)

Jessica FyeJ.P. Morgan

J.P. Morgan

―

Sell

―

Reiterated

06/24/25

J.P. Morgan Sticks to Its Sell Rating for Nektar Therapeutics (NKTR)

Andy HsiehWilliam Blair

William Blair

―

Hold

―

Reiterated

06/24/25

William Blair Sticks to Their Hold Rating for Nektar Therapeutics (NKTR)

Julian HarrisonBTIG

BTIG

$60→$100

Buy

236.93%

Upside

Reiterated

06/24/25

Nektar price target raised to $100 from $60 at BTIGNektar price target raised to $100 from $60 at BTIG

Roger SongJefferies

Jefferies

$69

Buy

132.48%

Upside

Reiterated

06/24/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jay OlsonOppenheimer

Oppenheimer

$90

Buy

203.23%

Upside

Upgraded

03/14/25

Mayank MamtaniB.Riley Financial

B.Riley Financial

$60

Buy

102.16%

Upside

Reiterated

02/28/25

Analysts Conflicted on These Healthcare Names: Lemaitre Vascular (NASDAQ: LMAT), Catalyst Pharma (NASDAQ: CPRX) and Nektar Therapeutics (NASDAQ: NKTR)

Anthony ButlerRodman & Renshaw

Rodman & Renshaw

$30

Buy

1.08%

Upside

Initiated

06/28/24

Nektar initiated with a Buy at Rodman & RenshawNektar initiated with a Buy at Rodman & Renshaw

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nektar Therapeutics

1 Month

xxx

Success Rate

9/17 ratings generated profit

Average Return

+1.58%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.94% of your transactions generating a profit, with an average return of +1.58% per trade.

3 Months

xxx

Success Rate

9/17 ratings generated profit

Average Return

+6.81%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +6.81% per trade.

1 Year

Julian HarrisonBTIG

Success Rate

5/6 ratings generated profit

Average Return

+74.37%

reiterated a buy rating 4 days ago

Copying Julian Harrison's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +74.37% per trade.

2 Years

xxx

Success Rate

5/6 ratings generated profit

Average Return

+74.37%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +74.37% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NKTR Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NKTR has received 9 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. NKTR average Analyst price target in the past 3 months is 98.50.

Each month's total comprises the sum of three months' worth of ratings.

NKTR Financial Forecast

NKTR Earnings Forecast

Next quarter’s earnings estimate for NKTR is -$2.92 with a range of -$3.79 to -$2.19. The previous quarter’s EPS was -$3.60. NKTR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.14% of the time in the same period. In the last calendar year NKTR has Outperformed its overall industry.

NKTR Sales Forecast

Next quarter’s sales forecast for NKTR is $9.49M with a range of $0.00 to $12.09M. The previous quarter’s sales results were $10.46M. NKTR beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year NKTR has Outperformed its overall industry.

NKTR Stock Forecast FAQ

What is NKTR’s average 12-month price target, according to analysts?

Based on analyst ratings, Nektar Therapeutics’s 12-month average price target is 98.50.

What is NKTR’s upside potential, based on the analysts’ average price target?

Nektar Therapeutics has 231.87% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NKTR a Buy, Sell or Hold?

Nektar Therapeutics has a consensus rating of Moderate Buy which is based on 4 buy ratings, 1 hold ratings and 1 sell ratings.

What is Nektar Therapeutics’s price target?

The average price target for Nektar Therapeutics is 98.50. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $69.00. The average price target represents 231.87% Increase from the current price of $29.68.

What do analysts say about Nektar Therapeutics?

Nektar Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of NKTR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Nektar Therapeutics (NKTR) Stock Forecast & Price Target

NKTR Analyst Ratings

NKTR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nektar Therapeutics

NKTR Analyst Recommendation Trends

NKTR Financial Forecast

NKTR Earnings Forecast

NKTR Sales Forecast

NKTR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts